Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)S26-S34
JournalDiabetes Research and Clinical Practice
Volume86
DOIs
Publication statusPublished - 2009

Cite this

@article{c8a432769d41439895fcd66787de8d0a,
title = "Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide",
author = "{van Genugten}, R.E. and {van Raalte}, D.H. and M. Diamant",
year = "2009",
doi = "10.1016/S0168-8227(09)70006-3",
language = "English",
volume = "86",
pages = "S26--S34",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. / van Genugten, R.E.; van Raalte, D.H.; Diamant, M.

In: Diabetes Research and Clinical Practice, Vol. 86, 2009, p. S26-S34.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

AU - van Genugten, R.E.

AU - van Raalte, D.H.

AU - Diamant, M.

PY - 2009

Y1 - 2009

U2 - 10.1016/S0168-8227(09)70006-3

DO - 10.1016/S0168-8227(09)70006-3

M3 - Article

VL - 86

SP - S26-S34

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -